CO2021007993A2 - Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina - Google Patents
Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobinaInfo
- Publication number
- CO2021007993A2 CO2021007993A2 CONC2021/0007993A CO2021007993A CO2021007993A2 CO 2021007993 A2 CO2021007993 A2 CO 2021007993A2 CO 2021007993 A CO2021007993 A CO 2021007993A CO 2021007993 A2 CO2021007993 A2 CO 2021007993A2
- Authority
- CO
- Colombia
- Prior art keywords
- hydroxyphenyloxymethyl
- formyl
- compounds capable
- hemoglobin
- modulating
- Prior art date
Links
- 102000001554 Hemoglobins Human genes 0.000 title abstract 3
- 108010054147 Hemoglobins Proteins 0.000 title abstract 3
- -1 2 ‐ formyl ‐ 3 ‐ hydroxyphenyloxymethyl compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La presente descripción se refiere en general a compuestos y composiciones farmacéuticas adecuadas como moduladores de la hemoglobina, y a métodos para su uso en el tratamiento de trastornos mediados por la hemoglobina.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769196P | 2018-11-19 | 2018-11-19 | |
| US201962821314P | 2019-03-20 | 2019-03-20 | |
| US201962848773P | 2019-05-16 | 2019-05-16 | |
| US201962883313P | 2019-08-06 | 2019-08-06 | |
| PCT/US2019/062054 WO2020106642A1 (en) | 2018-11-19 | 2019-11-18 | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021007993A2 true CO2021007993A2 (es) | 2021-06-30 |
Family
ID=68848454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0007993A CO2021007993A2 (es) | 2018-11-19 | 2021-06-18 | Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10683285B2 (es) |
| EP (2) | EP3880654B1 (es) |
| JP (1) | JP7509772B2 (es) |
| KR (1) | KR20210093990A (es) |
| CN (1) | CN113316568B (es) |
| AU (1) | AU2019383960B2 (es) |
| BR (1) | BR112021007044B1 (es) |
| CA (1) | CA3120380A1 (es) |
| CO (1) | CO2021007993A2 (es) |
| CR (1) | CR20210335A (es) |
| CY (1) | CY1125025T1 (es) |
| DK (1) | DK3880654T3 (es) |
| ES (1) | ES2908325T3 (es) |
| HR (1) | HRP20220295T1 (es) |
| HU (1) | HUE057323T2 (es) |
| IL (1) | IL283128B2 (es) |
| LT (1) | LT3880654T (es) |
| MA (1) | MA54231B1 (es) |
| MD (1) | MD3880654T2 (es) |
| MX (1) | MX2021005887A (es) |
| PL (1) | PL3880654T3 (es) |
| PT (1) | PT3880654T (es) |
| RS (1) | RS62970B1 (es) |
| SA (1) | SA521422031B1 (es) |
| SG (1) | SG11202104705RA (es) |
| SI (1) | SI3880654T1 (es) |
| SM (1) | SMT202200106T1 (es) |
| TW (1) | TWI841630B (es) |
| WO (1) | WO2020106642A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034922B1 (ru) | 2013-03-15 | 2020-04-07 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| AU2014237330A1 (en) | 2013-03-15 | 2015-09-17 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| ES2890077T3 (es) | 2013-03-15 | 2022-01-17 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de la hemoglobina |
| FI3102208T4 (fi) | 2014-02-07 | 2024-09-23 | Global Blood Therapeutics Inc | 2-hydroksi-6-((2-(1-isopropyyli-1h-pyratsol-5-yyli)pyridin-3-yyli)metoksi)bentsaldehydin vapaan emäksen kiteinen polymorfi |
| US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| NZ748072A (en) | 2017-03-20 | 2020-06-26 | Forma Therapeutics Inc | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| MA53668B1 (fr) | 2018-09-19 | 2024-06-28 | Novo Nordisk Health Care Ag | Traitement de la drépanocytose avec un composé activant la pyruvate kinase r |
| ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
| SI3880654T1 (sl) * | 2018-11-19 | 2022-04-29 | Global Blood Therapeutics, Inc. | 2-formil-3-hidroksifeniloksimetilne spojine, zmožne modulirati hemoglobin |
| AU2020349555A1 (en) | 2019-09-19 | 2022-04-07 | Forma Therapeutics, Inc. | Activating Pyruvate Kinase R |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| IL307906A (en) | 2021-05-14 | 2023-12-01 | Global Blood Therapeutics Inc | Methods for preparing a hemoglobin modulator |
| EP4337659A1 (en) * | 2021-05-14 | 2024-03-20 | Global Blood Therapeutics, Inc. | Solid forms of a modulator of hemoglobin |
| JP2024527819A (ja) | 2021-07-19 | 2024-07-26 | バイオアプリケーションズ インコーポレイテッド | 植物由来のｃｏｖｉｄ－１９変異組換えスパイクタンパク質発現ベクターおよび該発現ベクターを用いた組換えタンパク質 |
| AU2022408097A1 (en) * | 2021-12-10 | 2024-05-30 | Global Blood Therapeutics, Inc. | Methods of administering a modulator of hemoglobin |
| TW202515579A (zh) | 2023-06-13 | 2025-04-16 | 美商全球血液治療公司 | 投予血紅素的調節劑之方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| ZW14480A1 (en) | 1979-06-29 | 1982-03-17 | Wellcome Found | Pharmaceutical ethers preparation use and intermediates therefore and their preparation |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| GR76950B (es) | 1980-12-18 | 1984-09-04 | Wellcome Found | |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS63258463A (ja) | 1987-04-14 | 1988-10-25 | Kumiai Chem Ind Co Ltd | ２−フエノキシピリミジン誘導体及び除草剤 |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| EP0658559A1 (de) | 1993-12-14 | 1995-06-21 | Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. | Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren |
| NZ511927A (en) | 1998-12-14 | 2004-02-27 | F | Phenylglycine derivatives |
| MXPA01009733A (es) | 1999-03-31 | 2002-11-04 | Basf Ag | Diamidas del acido piridin-2,3-dicarboxilico. |
| CA2493908A1 (en) | 2002-08-08 | 2004-02-19 | Smithkline Beecham Corporation | Thiophene compounds |
| AU2003296022B2 (en) | 2002-12-04 | 2007-01-25 | Virginia Commonwealth University | Anti-sickling agents |
| KR20060017791A (ko) | 2003-06-12 | 2006-02-27 | 노보 노르디스크 에이/에스 | 호르몬-민감성 리파제 억제제로서의 피리디닐 카르바메이트 |
| WO2005102305A2 (en) | 2004-04-22 | 2005-11-03 | Allos Therapeutics, Inc. | Compositions of allosteric hemoglobin modifiers and methods of making the same |
| KR20080027908A (ko) | 2005-06-30 | 2008-03-28 | 프로시디온 리미티드 | Ｇｐｃｒ 효능제 |
| CN100562514C (zh) | 2005-07-22 | 2009-11-25 | 中国科学院上海药物研究所 | 一类取代丙酰胺衍生物、其制备方法和用途 |
| TW200835687A (en) | 2006-11-30 | 2008-09-01 | R Tech Ueno Ltd | Thiazole derivatives and their use as VAP-1 inhibitor |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| ES2599002T3 (es) | 2008-05-08 | 2017-01-31 | Nova Southeastern University | Inhibidores específicos para receptores del factor de crecimiento endotelial vascular |
| GB0811451D0 (en) | 2008-06-20 | 2008-07-30 | Syngenta Participations Ag | Novel microbiocides |
| TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
| DK2797416T3 (en) | 2011-12-28 | 2017-10-30 | Global Blood Therapeutics Inc | SUBSTITUTED BENZALDEHYD COMPOUNDS AND METHODS OF USING THEM IN INCREASED TISSUE OXIDATION |
| EP2797597B1 (en) | 2011-12-28 | 2020-02-26 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| ES2890077T3 (es) | 2013-03-15 | 2022-01-17 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de la hemoglobina |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA034922B1 (ru) * | 2013-03-15 | 2020-04-07 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US9422279B2 (en) * | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140271591A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US20150057251A1 (en) | 2013-08-26 | 2015-02-26 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| SG11201507351PA (en) * | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| WO2015031284A1 (en) | 2013-08-26 | 2015-03-05 | Global Blood Therapeutics, Inc. | Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s) |
| US20160207904A1 (en) | 2013-08-27 | 2016-07-21 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
| US20150141465A1 (en) | 2013-11-18 | 2015-05-21 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US9248199B2 (en) | 2014-01-29 | 2016-02-02 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
| FI3102208T4 (fi) | 2014-02-07 | 2024-09-23 | Global Blood Therapeutics Inc | 2-hydroksi-6-((2-(1-isopropyyli-1h-pyratsol-5-yyli)pyridin-3-yyli)metoksi)bentsaldehydin vapaan emäksen kiteinen polymorfi |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| TWI825524B (zh) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| SI3880654T1 (sl) * | 2018-11-19 | 2022-04-29 | Global Blood Therapeutics, Inc. | 2-formil-3-hidroksifeniloksimetilne spojine, zmožne modulirati hemoglobin |
-
2019
- 2019-11-18 SI SI201930191T patent/SI3880654T1/sl unknown
- 2019-11-18 US US16/687,474 patent/US10683285B2/en active Active
- 2019-11-18 EP EP19818401.2A patent/EP3880654B1/en active Active
- 2019-11-18 PL PL19818401T patent/PL3880654T3/pl unknown
- 2019-11-18 HR HRP20220295TT patent/HRP20220295T1/hr unknown
- 2019-11-18 CR CR20210335A patent/CR20210335A/es unknown
- 2019-11-18 ES ES19818401T patent/ES2908325T3/es active Active
- 2019-11-18 MD MDE20210907T patent/MD3880654T2/ro unknown
- 2019-11-18 MA MA54231A patent/MA54231B1/fr unknown
- 2019-11-18 LT LTEPPCT/US2019/062054T patent/LT3880654T/lt unknown
- 2019-11-18 JP JP2021527206A patent/JP7509772B2/ja active Active
- 2019-11-18 AU AU2019383960A patent/AU2019383960B2/en active Active
- 2019-11-18 DK DK19818401.2T patent/DK3880654T3/da active
- 2019-11-18 EP EP21217304.1A patent/EP4046988A1/en active Pending
- 2019-11-18 KR KR1020217018851A patent/KR20210093990A/ko active Pending
- 2019-11-18 SG SG11202104705RA patent/SG11202104705RA/en unknown
- 2019-11-18 TW TW108141848A patent/TWI841630B/zh active
- 2019-11-18 IL IL283128A patent/IL283128B2/en unknown
- 2019-11-18 RS RS20220126A patent/RS62970B1/sr unknown
- 2019-11-18 BR BR112021007044-3A patent/BR112021007044B1/pt active IP Right Grant
- 2019-11-18 CA CA3120380A patent/CA3120380A1/en active Pending
- 2019-11-18 WO PCT/US2019/062054 patent/WO2020106642A1/en active Application Filing
- 2019-11-18 CN CN201980088809.5A patent/CN113316568B/zh active Active
- 2019-11-18 PT PT198184012T patent/PT3880654T/pt unknown
- 2019-11-18 MX MX2021005887A patent/MX2021005887A/es unknown
- 2019-11-18 HU HUE19818401A patent/HUE057323T2/hu unknown
- 2019-11-18 SM SM20220106T patent/SMT202200106T1/it unknown
-
2020
- 2020-05-04 US US16/865,625 patent/US11548880B2/en active Active
-
2021
- 2021-05-17 SA SA521422031A patent/SA521422031B1/ar unknown
- 2021-06-18 CO CONC2021/0007993A patent/CO2021007993A2/es unknown
-
2022
- 2022-02-28 CY CY20221100163T patent/CY1125025T1/el unknown
- 2022-11-21 US US17/991,448 patent/US20230159507A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021007993A2 (es) | Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina | |
| MX2015011448A (es) | Compuestos y sus usos para modular la hemoglobina. | |
| MX2015011769A (es) | Compuestos y sus usos para modular la hemoglobina. | |
| UY38685A (es) | Moduladores de la vía de tensión integrada | |
| UY37617A (es) | Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo | |
| MX2015011445A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
| CL2021003257A1 (es) | Pirazolo-piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b. | |
| MX2019000588A (es) | Moduladores de la somatostatina y usos de los mismos. | |
| UY35425A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| DOP2021000251A (es) | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b | |
| CL2019000115A1 (es) | Compuestos y métodos para la modulación de smn2. | |
| NZ748817A (en) | Potassium channel modulators | |
| MX2020009602A (es) | Formulaciones de pulverizacion de epinefrina. | |
| MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
| CO2017012622A2 (es) | Moduladores alostéricos positivos del receptor muscarínico m2 | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CL2021000930A1 (es) | Piridazinas novedosas | |
| MX2024003249A (es) | Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona. | |
| BR112022008287A2 (pt) | Métodos de tratamento usando um modulador de mtorc1 | |
| CO2019008657A2 (es) | Composición intranasal que comprende betahistina | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| UA98759U (uk) | Спосіб друкування нанофотонних елементів активних і розумних паковань |